Hazardous drugs (NIOSH's list-group 1) in healthcare settings: Also a hazard for the environment?
S Domingo-Echaburu et al. Sci Total Environ. 2022.
Abstract
Healthcare workers can be exposed to dangerous drugs during their daily practice. The National Institute for Occupational Safety and Health (NIOSH) considers "hazardous drugs" as those that had shown one or more of the following characteristic in studies with animals, humans or in vitro systems: carcinogenicity, teratogenicity or other toxicity for development, reproductive toxicity, organ toxicity at low doses, or genotoxicity. In the actual list (draft list 2020), drugs classified in group 1 are those with carcinogenic effects. Moreover, the global human and veterinary cancer is expected to grow, so antineoplastic drug consumption may consequently grow, leading to an increase of anticancer pharmaceuticals in the environment. Not all drugs pertaining to group 1 can be classified as "antineoplastic" or "cytostatic". Since most of the research on environment presence and ecotoxicological effects of pharmaceuticals has been focused on this therapeutic class, other carcinogenic drugs belonging to different therapeutic groups may have been omitted in previous studies. In this study we aim to review the presence in the environment of the hazardous drugs (NIOSH group 1) and their possible environmental impact. Of the 90 drugs considered, there is evidence of presence in the environment for 19. Drugs with more studies reporting positive detections are: the antibiotic chloramphenicol (55), the alkylating agents cyclophosphamide (39) and ifosfamide (30), and the estrogen receptor modulator tamoxifen (18). Although the original purpose of the NIOSH list and related documents is to provide guidance to healthcare professionals in order to adequately protect them from the hazards posed by these drugs in healthcare settings, we believe they can be useful for environmentalists too. Absence of data regarding the potential of environmental risk of certain hazardous drugs might tell us which drugs ought to be prioritized in the future.
Keywords: Antineoplastic agents; Carcinogenic; Cytostatic; Endocrine disruptors; Hazardous drugs; Pharmaceuticals in the environment.
Copyright © 2022 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
Closed-system drug-transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff.
Gurusamy KS, Best LM, Tanguay C, Lennan E, Korva M, Bussières JF. Gurusamy KS, et al. Cochrane Database Syst Rev. 2018 Mar 27;3(3):CD012860. doi: 10.1002/14651858.CD012860.pub2. Cochrane Database Syst Rev. 2018. PMID: 29582940 Free PMC article. Review.
Conducting an evaluation of CBRN canister protection capabilities against emerging chemical and radiological hazards.
Greenawald LA, Karwacki CJ, Palya F, Browe MA, Bradley D, Szalajda JV. Greenawald LA, et al. J Occup Environ Hyg. 2020 Oct;17(10):480-494. doi: 10.1080/15459624.2020.1798452. Epub 2020 Aug 10. J Occup Environ Hyg. 2020. PMID: 32776823 Free PMC article.
How to Develop and Maintain a Hazardous Drug List.
Dillon LR. Dillon LR. Int J Pharm Compd. 2019 May-Jun;23(3):182-186. Int J Pharm Compd. 2019. PMID: 31085785
Hazardous drugs in health care settings--recognition and control.
Randolph SA. Randolph SA. Workplace Health Saf. 2012 Sep;60(9):412. doi: 10.1177/216507991206000907. Workplace Health Saf. 2012. PMID: 22938813
[Measures of preventing occupational exposure to hazardous drugs-based on new insights].
Sugiura S, Gohma H, Hamajima N. Sugiura S, et al. Gan To Kagaku Ryoho. 2014 Aug;41(8):923-5. Gan To Kagaku Ryoho. 2014. PMID: 25132022 Review. Japanese.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information